As the inhibition of DDR represents a valuable therapeutic option in cancer treatment that could work similarly to ATRA in the treatment of APL [108], targeting TRIM24 or genes belonging to the NER pathway could be considered a possible candidate for APL chemotherapy, as well as patient treatment with alkylating or platinum agents [109]. The gene discussed is TRIM24; the disease is acute promyelocytic leukemia.